Resverlogix (RVX) Competitors C$0.10 +0.01 (+11.11%) As of 08/1/2025 03:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock RVX vs. ONC, SCYB, COM, APS, NVH, IGX, COV, PDP, SVA, and MDNAShould you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Aptose Biosciences (APS), Novoheart (NVH), IntelGenx Technologies (IGX), Covalon Technologies (COV), Pediapharm (PDP), Sernova (SVA), and Medicenna Therapeutics (MDNA). These companies are all part of the "biotechnology" industry. Resverlogix vs. Its Competitors Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Aptose Biosciences Novoheart IntelGenx Technologies Covalon Technologies Pediapharm Sernova Medicenna Therapeutics Resverlogix (TSE:RVX) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has higher valuation & earnings, RVX or ONC? Resverlogix is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResverlogixN/AN/A-C$2.81M-C$0.02-4.95Oncolytics BiotechN/AN/A-C$27.66M-C$0.36-3.82 Do analysts prefer RVX or ONC? Oncolytics Biotech has a consensus target price of C$3.50, suggesting a potential upside of 155.47%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Resverlogix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Resverlogix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, RVX or ONC? Resverlogix has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Do institutionals & insiders hold more shares of RVX or ONC? 1.8% of Oncolytics Biotech shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Comparatively, 3.8% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is RVX or ONC more profitable? Resverlogix's return on equity of 6.06% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets ResverlogixN/A 6.06% -34.90% Oncolytics Biotech N/A -141.94%-71.33% Does the media favor RVX or ONC? In the previous week, Oncolytics Biotech had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Oncolytics Biotech and 0 mentions for Resverlogix. Resverlogix's average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.66 indicating that Resverlogix is being referred to more favorably in the media. Company Overall Sentiment Resverlogix Neutral Oncolytics Biotech Negative SummaryResverlogix and Oncolytics Biotech tied by winning 6 of the 12 factors compared between the two stocks. Get Resverlogix News Delivered to You Automatically Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVX vs. The Competition Export to ExcelMetricResverlogixBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$19.79MC$134.51MC$5.49BC$6.20BDividend Yield7.02%3.74%4.73%6.72%P/E Ratio-4.953.8128.7863.43Price / SalesN/A4,246.60372.201,250.99Price / Cash132.5013.1935.4583.29Price / Book-0.4339.388.274.87Net Income-C$2.81M-C$90.99MC$3.25BC$301.20M7 Day PerformanceN/A-1.84%-3.70%-2.26%1 Month PerformanceN/A11.20%4.34%0.80%1 Year PerformanceN/A189.79%25.90%26.62% Resverlogix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVXResverlogixN/AC$0.10+11.1%N/A+100.0%C$19.79MN/A-4.9519Gap UpHigh Trading VolumeONCOncolytics Biotech1.2443 of 5 starsC$1.53-5.0%C$3.50+128.8%-7.4%C$117.92MN/A-4.2629SCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/AAPSAptose BiosciencesN/AC$2.34-1.7%N/A-92.3%C$100.76MN/A-0.4731News CoverageGap UpNVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap UpCOVCovalon TechnologiesN/AC$2.62+3.6%N/A+6.5%C$71.78MC$27.87M30.07N/APDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/ASVASernova1.9457 of 5 starsC$0.20+11.4%C$2.00+925.6%-32.1%C$65.62MN/A-1.881,959Gap UpMDNAMedicenna TherapeuticsN/AC$0.83-2.4%N/A-63.2%C$62.10MC$4.87K-2.2920 Related Companies and Tools Related Companies Oncolytics Biotech Competitors Scythian Biosciences Competitors 138267 (COM.TO) Competitors Aptose Biosciences Competitors Novoheart Competitors IntelGenx Technologies Competitors Covalon Technologies Competitors Pediapharm Competitors Sernova Competitors Medicenna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:RVX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVX Stock Alerts